However, using the eligibility criteria of a different PSMA RLT trial in prostate cancer (TheraP, [22]) (at least one lesion with SUVmax > 20, and no lesion > 10 mm with SUVmax < 10 on PSMA PET), no patients in our cohort would qualify for PSMA RLT. This evidence concerns the gene FOLH1 and prostate cancer.